BACKGROUND: The authors performed a phase 2 trial of combined protracted daily @entity2903 and biweekly bevacizumab for @entity1 with recurrent @entity463 who had previously received radiation therapy and @entity2903 . METHODS: There was no limit on the number of previous disease progressions or previous regimens allowed. Thirty-two adult @entity1 were enrolled. @entity1 received @entity2903 50 mg/m(2) daily and bevacizumab 10 mg/kg intravenously every 14 days. @entity1 underwent physical examination and brain magnetic resonance imaging every 8 weeks. RESULTS: The authors observed a 6-month progression-free survival (PFS) rate of 18.8% (95% confidence interval [CI], 7.6%-33.7%) and a median PFS of 15.8 weeks. The median @entity1349 ( @entity1349 ) was 37 weeks, the 6-month @entity1349 rate was 62.5% (95% CI, 43.5%-76.7%), and the 12-month @entity1349 rate was 31.3% (95% CI, 16.4%-47.3%). Nine @entity1 (28%) had a radiographic response, and 7 @entity1 (22%) had disease progression within the first 8 weeks of treatment. Patterns of progression were available for 21 @entity1 . The authors observed that 52% of @entity1 (n = 11) progressed locally, 38% (n = 8) progressed with a diffuse pattern, and 10% (n = 2) progressed at a distant site. Two @entity1 discontinued therapy secondary to @entity137 (prolonged @entity882 and grade 4 @entity788 ). One @entity1 experienced grade 5 @entity55 . CONCLUSIONS: The current study demonstrated that a regimen of combined daily @entity2903 and biweekly bevacizumab had some activity and was well tolerated. However, the results obtained in this study were inferior to those observed in studies of bevacizumab monotherapy and of combined @entity2600 and bevacizumab therapy. The current @entity1 population was more heterogeneous and was pretreated more heavily than @entity1 in previous studies.

Bevacizumab and daily @entity2903 for recurrent XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'patient'] @entity788 :: ('MESH:D010190', 'Disease') :: ['pancreatitis'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonia'] @entity2903 :: ('MESH:C047246', 'Chemical') :: ['temozolomide'] @entity463 :: ('MESH:D005909', 'Disease') :: ['glioblastoma'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity463 :: (MESH:D005909,Disease) :: ['glioblastoma']
